CCCC is trading 5.6% up at $4.37 following renewed interest in Phase 1 cemsidomide data for relapsed/refractory multiple myeloma.
- Updated clinical results showed a 53% overall response rate at the recommended Phase 2 dose with a manageable safety profile.
- The upward move is primarily driven by the clinical update and follow-on development plans, supported by a broader increase in biotech risk appetite.